Distalising tibial tubercle osteotomy decreases patellar tendon force - A treatment rationale for recalcitrant patellar tendinopathy.


Journal

The Knee
ISSN: 1873-5800
Titre abrégé: Knee
Pays: Netherlands
ID NLM: 9430798

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 07 09 2019
revised: 19 12 2019
accepted: 27 02 2020
pubmed: 30 3 2020
medline: 15 12 2020
entrez: 30 3 2020
Statut: ppublish

Résumé

Patellar tendinopathy is an overuse condition affecting athletes, often with a high morbidity if left untreated. High-level evidence fails to support the use of surgery. A tibial tubercle osteotomy (TTO) has been suggested as a surgical option to improve patient outcomes. Our aim was to explore whether a distalising TTO will alter the patellar tendon to quadriceps tendon force ratio and the sagittal patellar tilt. Six cadaver limbs were placed in a custom jig with a mechanical testing machine applying cyclical loads of 200-500 N to the quadriceps tendon. The knee was fixed at 0, 15, 30, 45, 60, 75 and 90° of flexion and a buckle transducer recorded the resultant patellar tendon force. Testing was performed with the native tibial tubercle position and with the tubercle distalised by 11 mm. Testing was also performed with the tubercle anteriorised by 10 mm at both of these tubercle positions, a total of four different testing positions. There was a significant decrease in the patellar tendon to quadriceps tendon force ratio from 30-60° of knee flexion. There was a significant increase in the sagittal patellar tilt at 30° of knee flexion with distalisation. This biomechanical study shows that the patellar tendon to quadriceps tendon force ratio can be altered with a distalising tibial tubercle osteotomy. A tibial tubercle osteotomy may be a biomechanical treatment option for recalcitrant patellar tendinopathy by decreasing the load through the patellar tendon, allowing the athlete to maintain higher training volumes and loads.

Sections du résumé

BACKGROUND BACKGROUND
Patellar tendinopathy is an overuse condition affecting athletes, often with a high morbidity if left untreated. High-level evidence fails to support the use of surgery. A tibial tubercle osteotomy (TTO) has been suggested as a surgical option to improve patient outcomes. Our aim was to explore whether a distalising TTO will alter the patellar tendon to quadriceps tendon force ratio and the sagittal patellar tilt.
METHODS METHODS
Six cadaver limbs were placed in a custom jig with a mechanical testing machine applying cyclical loads of 200-500 N to the quadriceps tendon. The knee was fixed at 0, 15, 30, 45, 60, 75 and 90° of flexion and a buckle transducer recorded the resultant patellar tendon force. Testing was performed with the native tibial tubercle position and with the tubercle distalised by 11 mm. Testing was also performed with the tubercle anteriorised by 10 mm at both of these tubercle positions, a total of four different testing positions.
RESULTS RESULTS
There was a significant decrease in the patellar tendon to quadriceps tendon force ratio from 30-60° of knee flexion. There was a significant increase in the sagittal patellar tilt at 30° of knee flexion with distalisation.
CONCLUSION CONCLUSIONS
This biomechanical study shows that the patellar tendon to quadriceps tendon force ratio can be altered with a distalising tibial tubercle osteotomy. A tibial tubercle osteotomy may be a biomechanical treatment option for recalcitrant patellar tendinopathy by decreasing the load through the patellar tendon, allowing the athlete to maintain higher training volumes and loads.

Identifiants

pubmed: 32220536
pii: S0968-0160(20)30060-0
doi: 10.1016/j.knee.2020.02.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

871-877

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Michael J Dan (MJ)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia. Electronic address: michaeldan@hotmail.com.

Joseph Cadman (J)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia. Electronic address: joseph.cadman@mq.edu.au.

James McMahon (J)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia.

William C H Parr (WCH)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia. Electronic address: w.parr@unsw.edu.au.

David Broe (D)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia.

Mervyn Cross (M)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia.

Richard Appleyard (R)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia. Electronic address: richard.appleyard@mq.edu.au.

William R Walsh (WR)

Surgical and Orthopaedic Research Laboratory of the University of NSW Clinical School at Prince of Wales Hospital, Randwick, Australia; Faculty of Medicine and Health Science, Macquarie University, North Ryde, Australia. Electronic address: w.walsh@unsw.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH